Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.

Expert review of hematology - 1 Apr 2014

Gianelli Umberto, Iurlo Alessandra, Cattaneo Daniele, Lambertenghi-Deliliers Giorgio

Abstract excerpt

As no specific genetic lesions have yet been identified, the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms is based on a simultaneous evaluation of the clinical, morphological and molecular features defined by the updated WHO classification, which allow most cases of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow
Share to JAK2 gene
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Megakaryocytes

Share to Mutation

Share to Primary Myelofibrosis

Share to Protein Kinase Inhibitors

Share to Thrombocytosis

Source

Identifiers

PMID: 24524231
DOI: 10.1586/17474086.2014.876898

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24524231-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.PMID 24524231Read ↗

Prodromal myeloproliferative neoplasms: the 2008 WHO classification.Semantic proximity Read ↗

[Current diagnosis of myeloproliferative neoplasms (2008 WHO classification)].Semantic proximity Read ↗

Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs).Semantic proximity Read ↗

Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture.Semantic proximity Read ↗

[CURRENT CRITERIA FOR THE DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS - WHAT IS IMPORTANT TO KNOW?]Semantic proximity Read ↗

The 2008 World Health Organization classification system for myeloproliferative neoplasmsSemantic proximity Read ↗

The myeloproliferative neoplasms: insights into molecular pathogenesis and changes in WHO classification and criteria for diagnosis.Semantic proximity Read ↗

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.Semantic proximity Read ↗

World Health Organization Classification, Evaluation, and Genetics of the Myeloproliferative Neoplasm VariantsSemantic proximity Read ↗

Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology.Semantic proximity Read ↗

Philadelphia-Negative MPN: A Molecular Journey, from Hematopoietic Stem Cell to Clinical Features.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.